Calcimedica, INC 8-K filings

CalciMedica has increased the maximum aggregate offering price of its common stock under an existing at-the-market offering agreement to $17,068,386.

CalciMedica reported its 2023 financial results, highlighted clinical trial progress, and secured funding to extend its operational runway into the second half of 2025.

CalciMedica has received FDA clearance for a Phase 2 trial of Auxora in acute kidney injury and anticipates data readouts for multiple trials in 2024 and 2025.

CalciMedica has announced a private placement to raise up to $55 million, including $20.4 million upfront, to fund clinical trials for its drug candidate Auxora.

CalciMedica has announced a private placement to raise up to $55 million to fund its clinical trials for Auxora in acute pancreatitis and acute kidney injury.